Express Scripts (NASDAQ:ESRX) is scheduled to release its earnings data after the market closes on Wednesday, May 2nd. Analysts expect Express Scripts to post earnings of $1.76 per share for the quarter. Express Scripts has set its Q1 guidance at $1.73-1.78 EPS and its FY18 guidance at $9.27-9.47 EPS.
Express Scripts (NASDAQ:ESRX) last issued its quarterly earnings results on Tuesday, February 27th. The company reported $2.16 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.09 by $0.07. The firm had revenue of $25.38 billion during the quarter, compared to analysts’ expectations of $25.07 billion. Express Scripts had a net margin of 4.51% and a return on equity of 25.19%. Express Scripts’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.88 EPS. On average, analysts expect Express Scripts to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.
Shares of NASDAQ:ESRX opened at $75.49 on Wednesday. The firm has a market cap of $42,221.52, a P/E ratio of 10.56, a price-to-earnings-growth ratio of 0.92 and a beta of 0.99. The company has a quick ratio of 0.55, a current ratio of 0.67 and a debt-to-equity ratio of 0.83. Express Scripts has a 1-year low of $55.80 and a 1-year high of $85.07.
A number of brokerages recently weighed in on ESRX. Sanford C. Bernstein cut shares of Express Scripts from a “market perform” rating to an “underperform” rating and increased their price target for the stock from $55.80 to $77.50 in a research note on Tuesday, January 30th. BidaskClub downgraded shares of Express Scripts from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 2nd. Jefferies Group set a $91.00 price objective on shares of Express Scripts and gave the stock a “buy” rating in a research report on Wednesday, February 28th. William Blair downgraded shares of Express Scripts from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 8th. Finally, ValuEngine downgraded shares of Express Scripts from a “buy” rating to a “hold” rating in a research report on Monday, April 2nd. Three research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $81.97.
In other news, VP Everett Neville sold 4,895 shares of the stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $75.26, for a total value of $368,397.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christine Houston sold 19,889 shares of the stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $76.69, for a total transaction of $1,525,287.41. The disclosure for this sale can be found here. 0.79% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/25/express-scripts-esrx-to-release-earnings-on-wednesday.html.
Express Scripts Company Profile
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.